HC Wainwright Reaffirms Buy Rating for OPKO Health (NASDAQ:OPK)

HC Wainwright reissued their buy rating on shares of OPKO Health (NASDAQ:OPK - Free Report) in a research note released on Monday,Benzinga reports. They currently have a $3.00 price target on the biotechnology company's stock. HC Wainwright also issued estimates for OPKO Health's Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.31) EPS.

A number of other equities analysts also recently issued reports on the stock. Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, February 28th. StockNews.com lowered OPKO Health from a "hold" rating to a "sell" rating in a research report on Wednesday, January 15th.

OPKO Health Trading Down 2.6 %

Shares of OPK stock traded down $0.05 during trading hours on Monday, reaching $1.89. The company's stock had a trading volume of 5,280,229 shares, compared to its average volume of 4,746,894. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a one year low of $0.86 and a one year high of $2.04. The stock has a market capitalization of $1.29 billion, a P/E ratio of -9.95 and a beta of 1.63. The firm's fifty day simple moving average is $1.57 and its 200 day simple moving average is $1.56.

Remove Ads

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. Equities research analysts expect that OPKO Health will post -0.25 EPS for the current year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average cost of $1.56 per share, with a total value of $780,000.00. Following the completion of the purchase, the chief executive officer now owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. The trade was a 0.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 1,389,971 shares of company stock valued at $2,124,442 in the last three months. Company insiders own 47.26% of the company's stock.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP raised its holdings in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock worth $72,573,000 after buying an additional 4,284,336 shares during the last quarter. Barclays PLC raised its holdings in OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock worth $810,000 after acquiring an additional 329,870 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in OPKO Health by 736.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 217,450 shares during the last quarter. Intech Investment Management LLC bought a new position in OPKO Health in the 3rd quarter valued at approximately $190,000. Finally, FMR LLC boosted its stake in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.